Identification and characterization of the in-vivo metabolites of the novel soluble epoxide hydrolase inhibitor EC5026 using liquid chromatography quadrupole time of flight mass spectrometry.

EC5026 is a novel soluble epoxide hydrolase inhibitor being developed clinically to treat neuropathic pain and inflammation. In the current study, we employed the LC-ESI-Q-TOF-MS/MS technique to identify four in-vivo phase-I metabolites of EC5026 in rat model, out of which three were found to be novel. The identified metabolites include aliphatic hydroxylation, di-hydroxylation, terminal desaturation, and carboxylation.

Development and validation of LC-MS/MS method for estimating the pharmacokinetics, protein binding, and metabolic stability of soluble epoxide hydrolase inhibitor EC5026.

EC5026 is a soluble epoxide hydrolase (SEH) inhibitor which is being developed clinically (Phase-1) as a first-in-class analgesic for the treatment of pain. In the present study, we report the development and validation of the LC-MS/MS method for the estimation of EC5026 from rat plasma. The developed method is simple, specific, and sensitive for the quantification of EC5026 from rat plasma.